Novel Therapeutic Agents in Waldenström’s Macroglobulinemia

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström’s macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and hist...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Ghobrial, Irene M., Leleu, Xavier, Azab, Abdel Kareem, Runnels, Judith, Jia, Xiaoying, Ngo, Hai, Melhem, Molly, Azab, Feda, Sacco, Antonio, Quang, Phong, Burwick, Nicholas, Moreau, Anne-Sophie, Husu, Emanuel, Farag, Mena, Roccaro, Aldo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3133646/
https://ncbi.nlm.nih.gov/pubmed/19362982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLM.2009.n.022
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller